Ultragenyx shareholders OK 14.5M-share equity plan; re-elect directors

Ultragenyx Pharmaceutical Inc.

Third Amended and Restated 2023 Incentive Plan approved; up to 14.5M new shares available plus shares from prior plans.
Emil Kakkis, Shehnaaz Suliman, Daniel G. Welch re-elected as Class I directors to serve until 2029 Annual Meeting.
Ernst & Young ratified as independent auditor; advisory 'say-on-pay' proposal passed with 70.9M votes for.
Director compensation limit set at $900k per year ($1.5M for first year or Chair/Lead Director).

item 5.02item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.